Regeneron Pharmaceuticals (REGN) Other Non-Current Assets (2009 - 2026)

Regeneron Pharmaceuticals has reported Other Non-Current Assets for 18 years, with the latest figure at $2.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 52.87% year-over-year to $2.1 billion; the trailing twelve-month figure through Mar 2026 stood at $2.1 billion (up 52.87% YoY), and the FY2025 full-year result was $1.8 billion, up 60.32% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $2.1 billion, up from $1.8 billion in the prior quarter.
• The five-year high for Other Non-Current Assets was $2.1 billion in Q1 2026, with the low at $262.0 million in Q1 2022.
• Average Other Non-Current Assets over 5 years is $881.3 million, with a median of $470.2 million recorded in 2024.
• Year-over-year, Other Non-Current Assets advanced 28.01% in 2023 and soared 196.28% in 2025.
• Tracing REGN's Other Non-Current Assets over 5 years: stood at $336.4 million in 2022, then jumped by 32.02% to $444.1 million in 2023, then jumped by 155.8% to $1.1 billion in 2024, then soared by 60.32% to $1.8 billion in 2025, then gained by 16.94% to $2.1 billion in 2026.
• The last three Other Non-Current Assets figures came in at $2.1 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.7 billion (Q3 2025), per Business Quant data.

Peer Comparison